Articlenpj biomedical innovations2025
Bacterial hitchhiking with drug-loaded nanoparticles as a drug delivery strategy for cancer immunotherapy.
Article in npj biomedical innovations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Preclinical Optimization of Magnetotactic Bacteria Therapy for the Treatment of Pancreatic and Rectal Cancer.Cancers · 2026Article
- Bioengineered bacteria in cancer immunotherapy: mechanistic advances, therapeutic strategies and clinical potential.Archives of microbiology · 2026Review
- Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- A biohybrid platform integrating bacterial propulsion and photoresponsive nanomedicine for adequate intratumoral drug delivery.Journal of nanobiotechnology · 2026Article
- From Mechanism to Clinic: Engineered Bacteria-Nanomaterial Hybrid Systems for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Article
- Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits.Journal of hematology & oncology · 2025Review
- Recent advances of engineered probiotics for therapeutic applications.Biodesign research · 2025Review
- Elucidating the Drug Delivery Mechanism in Porous Antibody Implants Using Molecular Simulations and Graph Theory.The journal of physical chemistry. B · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Select strains of bacteria show significant therapeutic promise in oncology, but there are major limitations for their clinical implementation, including their fast clearance from the circulation and dose-limiting toxicity. To address this challenge, we propose delivering bacteria alongside drug-loaded nanoparticles to reduce the premature clearance of bacteria from the circulation and improve their therapeutic efficacy. We evaluated the ability of the bacterium Magnetospirillum gryphiswaldense, an environmental isolate that holds promise as an anti-cancer immunotherapy, to carry drug-loaded nanoliposomes into melanoma tumors. Using the B16F10 melanoma mouse model, we demonstrated that when injected locally, the bacteria can significantly reduce tumor growth while inducing a strong immune response. Further, we showed that drug-loaded nanoliposomes can be conjugated to the surface of bacteria improving their tumoral delivery and yielding a stronger anticancer response when delivered systemically. These results suggest that bacterial hitchhiking is a promising systemic drug delivery strategy for cancer immunotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.